Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments - Featured image
GLP-1 Medications

AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·January 15, 2026·1 min read

On this page

  • AbbVie's Amylin-Based Strategy
  • Commercial Edge and Market Potential
  • Key Advantages Over GLP-1 Therapies

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.

Share

On this page

  • AbbVie's Amylin-Based Strategy
  • Commercial Edge and Market Potential
  • Key Advantages Over GLP-1 Therapies

AbbVie aims to capture a slice of the rapidly expanding obesity treatment market by developing GUBamy, a therapy licensed from Danish biotech Gubra in 2023.

AbbVie's Amylin-Based Strategy

This innovative treatment, rooted in the pancreatic hormone amylin, offers a fresh alternative to established GLP-1 agonists such as Wegovy (Novo Nordisk) and Zepbound (Eli Lilly). Amylin influences gastric emptying and appetite differently from GLP-1 drugs, which mimic gut hormones.

Key Advantages Over GLP-1 Therapies

  • Better tolerability: Early data points to fewer side effects for patients.
  • Durable effectiveness: Ideal for those struggling with weight regain on first-generation options.
  • Muscle mass preservation: Potential to maintain lean body mass during weight loss.

AbbVie is advancing a long-acting version of the molecule to speed up clinical trials. At the J.P. Morgan Healthcare Conference, executives highlighted the need for sustainable solutions beyond current GLP-1 limitations.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Commercial Edge and Market Potential

AbbVie leverages synergies with its medical-aesthetics business, sharing overlapping customers with weight loss treatments. This positions the company competitively against market leaders.

With the global obesity drug market projected to reach $150 billion annually in the next decade, AbbVie banks on amylin’s unique mechanism and established infrastructure for differentiation.

Source Information

Originally published by Market Screener.Read the original article →

Read next

Keep exploring

More on Wegovy

Articles covering Wegovy dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: AbbVie

All AbbVie articles →
Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline
GLP-1 Medications & Biotech

Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline

Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.

5 min read
Ireland's Each-Way Bet on Wegovy and Mounjaro Rivals
Pharmaceutical Industry

Ireland's Each-Way Bet on Wegovy and Mounjaro Rivals

A spectacular backfire in Novo Nordisk's head-to-head trial against Eli Lilly's Mounjaro has widened the gap in the weight loss drug race, yet Ireland stands to gain from both giants. With billions in investments, thousands of jobs, and massive tax revenues, the Republic is placing an each-way bet on Wegovy and Mounjaro. This economic tie underscores pharma's pivotal role in Ireland's prosperity.

6 min read
FDA Approvals for 2025
Pharmaceuticals

FDA Approvals for 2025

In 2025, the FDA approved 46 novel therapeutic agents from its Center for Drug Evaluation and Research, marking a slight dip from the five-year average but remaining above historical norms. Cancer led approvals, with advancements in modalities like kinase inhibitors and gene therapies. The year also introduced new programs and faced staffing challenges under changing leadership.

13 min read

More in GLP-1 Medications

FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds
GLP-1 Medications

FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds

The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.

4 min read
Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed
GLP-1 Medications

Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed

Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.

2 min read
Wegovy Pill: 18,410 Prescriptions in First Full Week
GLP-1 Medications

Wegovy Pill: 18,410 Prescriptions in First Full Week

Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.

1 min read
Share this article
  1. Home
  2. Blog
  3. AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community